| Literature DB >> 35801148 |
Molly Deutsch-Feldman1,2, Yuri P Springer1, Derrick Felix1, Clarisse A Tsang1, Richard Brostrom1, Maryam Haddad1.
Abstract
Background: In recent years, tuberculosis (TB) incidence in the United States has declined overall but remained high among Native Hawaiian and Other Pacific Islander (NH/PI) persons. Few studies have examined the epidemiology of TB among NH/PI persons, particularly in the U.S.-Affiliated Pacific Islands (USAPI). We describe TB incidence and characteristics of NH/PI patients during 2010-2019.Entities:
Keywords: U.S.-Affiliated Pacific Islands; tuberculosis
Year: 2022 PMID: 35801148 PMCID: PMC9257550 DOI: 10.1089/heq.2022.0065
Source DB: PubMed Journal: Health Equity ISSN: 2473-1242
Demographic and Clinical Characteristics of Non-Hispanic Native Hawaiian and Other Pacific Islander and Asian Persons with Tuberculosis Disease, 2010–2019
| Characteristic | ||||
|---|---|---|---|---|
| NH/PI 50 states[ | NH/PI USAPI[ | Asian[ | White[ | |
| Total number of cases | 205 | 4154 | 29,901 | 10,119 |
| Sex | ||||
| Male | 111 (54) | 2157 (52)[ | 17,089 (57) | 6944 (69) |
| Female | 94 (46) | 1997 (48)[ | 12,812 (43) | 3175 (31) |
| Age (years) | ||||
| 0–4 | 69 (34)[ | 438 (11)[ | 122 (<1) | 188 (2) |
| 5–14 | 41 (20) | 558 (13) | 247 (1) | 84 (1) |
| 15–24 | 29 (14) | 707 (17) | 2598 (9) | 335 (3) |
| 25–44 | 30 (15) | 1165 (28) | 8899 (30) | 1649 (16) |
| 45–64 | 22 (11) | 1008 (24) | 9000 (30) | 4216 (42) |
| ≥65 | 14 (7) | 277 (7) | 9033 (30) | 3646 (36) |
| Ethnicity[ | ||||
| Chamorro | <5 (1) | 180 (4) | ||
| Fijian | <5 (<1) | <5 (0) | ||
| Kiribati | <5 (0) | <5 (<1) | ||
| Marshallese | 25 (12) | 1967 (47) | ||
| Micronesian | 34 (17) | 1555 (37) | ||
| Native Hawaiian | 24 (12) | <5 (<1) | ||
| Palauan | <5 (1) | 94 (2) | ||
| Samoan | 15 (7) | 21 (1) | ||
| Tongan | 14 (7) | <5 (0) | ||
| Other | 11 (5) | 27 (1) | ||
| Not reported | 78 (38) | 307 (7) | ||
| Clinical characteristics | ||||
| Diabetes mellitus at time of diagnosis | 20 (10)[ | 832 (20)[ | 6506 (22) | 1253 (12) |
| HIV positive at time of diagnosis[ | <5 (0) | <5[ | 359 (1) | 296 (3) |
| End-stage renal disease or chronic renal failure at time of diagnosis | 5 (2) | 44 (1)[ | 904 (3) | 169 (2) |
| Immunosuppressed at time of diagnosis[ | 7 (3) | 41 (1)[ | 1794 (6) | 1088 (11) |
| Diagnostic criteria | ||||
| Smear positive[ | 37 (35) | 1277 (36)[ | 10,364 (40) | 4092 (49) |
| Culture positive[ | 61 (58) | 1600 (49)[ | 16,866 (66) | 5797 (70) |
| Disease status | ||||
| Any pulmonary disease | 171 (83)[ | 3453 (83)[ | 22,950 (77) | 8718 (86) |
| Any extrapulmonary disease | 73 (36) | 960 (23)[ | 10,077 (34) | 2097 (21) |
| Cavitary pulmonary disease[ | 26 (13)[ | 921 (22)[ | 7167 (24) | 3597 (36) |
| Miliary disease[ | 11 (6)[ | 144 (4)[ | 859 (3) | 349 (4) |
| Meningeal disease | 8 (4)[ | 8 (<1)[ | 371 (1) | 109 (1) |
| Completed TB treatment[ | 166 (94) | 2953 (90) | 23,289 (89) | 8159 (86) |
This table includes all single-race, non-Hispanic NH/PI persons and single-race, non-Hispanic Asian persons born in Asia diagnosed with TB disease between 2010 and 2019.
Values <5 are presented as “<5.”
NH/PI 50 states includes all single-race NH/PI persons who reported being born in the 50 U.S. states or Washington, DC; NH/PI USAPI includes all single-race NH/PI persons who reported being born in the USAPI; Asian includes all single-race Asian persons who reported being born in Asia; White includes all single-race White persons who reported being born in the 50 U.S. states or Washington, DC.
Micronesian includes Carolinian, Chuukese, Kosrean, Micronesian, Pohnpeian, and Yapese; Chamorro includes Chamorro, Guamanian, and Saipanese; Other includes Mariana Islander, Melanesian, New Herbides, Other Pacific Islander, Polynesian, Solomon Islander, and Tokelauan.
2011–2019 only.
Includes patients who had immunosuppression due to either a medical condition or medication, or immunosuppressive therapy, excluding diabetes mellitus, end-stage renal disease, HIV/AIDS, and patients who had recently received, or were receiving, TNF-α antagonist therapy at the time of TB diagnosis.
Proportions calculated only among patients with available test results.
Includes only persons with any pulmonary TB and any evidence of cavitation on chest radiograph or computerized tomography scan.
Any evidence of miliary disease on chest radiograph.
Numbers and percentages are based on patients with complete outcome data with a 2 year lag (i.e., cases reported during 2010–2018) so that outcome data could be documented in the 2010–2020 dataset.
Indicates p<0.05 for the chi-squared test or Fisher's exact test comparing the indicated proportion with that of the Asian analytic group. For the age variable, group-wise comparisons were performed.
NH/PI, Native Hawaiian and Other Pacific Islander; TB, tuberculosis; USAPI, U.S.-Affiliated Pacific Islands.
FIG. 1.Annual incidence of TB disease (cases per 100,000 persons) among non-Hispanic, single-race NH/PI, Asian and White persons by place of birth, 2010–2019. Incidence calculated as quotient of (1) number of NH/PI TB patients born in the U.S. states and estimated number of NH/PI persons born in the U.S states, (2) number of NH/PI TB patients born in the USAPI and estimated number of NH/PI persons born in the USAPI, (3) number of White TB patients born in the U.S. states and estimated number of White persons born in the U.S states, and (4) number of Asian TB patients born in Asia and estimated number of Asian persons born in Asia. See Supplementary Text for additional details regarding population denominator estimates. Note: multiple mass screening events to identify cases of active TB were conducted in the Republic of the Marshall Islands starting in 2017. NH/PI, Native Hawaiian and Pacific Islander; TB, tuberculosis; USAPI, U.S.-Affiliated Pacific Islands.
FIG. 2.Crude annual TB incidence (per 100,000 persons) among NH/PI persons with TB disease reporting being born in the USAPI by region, 2010–2019. Incidence proportions calculated for each region/year as the quotient of the number of TB cases reported among NH/PI persons reporting being born in any of the six USAPI regions and estimated number of NH/PI persons reporting being born in each region (see Supplementary Text for additional details regarding population estimates). Note: multiple mass screening events to identify cases of active TB were conducted in the Republic of the Marshall Islands starting in 2017.
FIG. 3.Crude annual TB incidence (per 100,000 persons) among NH/PI persons with TB disease reporting being born in the 50 States among the four Department of Health and Human Service regions with highest median incidence, 2010–2019. Incidence proportions calculated for each region/year as the quotient of the number of TB cases reported among NH/PI persons reporting being born in the 50 states and estimated number of NH/PI persons reporting being born in each HHS region. See Supplemental Text for information regarding population estimates. Note: the small numerators (<5) for many of these calculations yield highly variable incidence estimates that are not statistically reliable. HHS, U.S. Department of Health and Human Services.
FIG. 4.PRs comparing frequency of selected characteristics among NH/PI TB patients (50 states and USAPI) with Asian patients. PRs calculated as the proportion of NH/PI TB patients aged ≥15 years, stratified by place of birth, reporting each characteristic divided by the proportion of Asian TB patients aged ≥15 years reporting each characteristic. See Supplementary Table 1 for additional details. For TB cases reported to NTSS during 2010–2019, patients with unknown or missing information for a characteristic were excluded from PR calculations for that characteristic. The dashed line represents a null value of PR=1. aIncludes both injection and non-injection drug use. bSmear, sputum smear; restricted patients with pulmonary disease and patients with available information. NTSS, National Tuberculosis Surveillance System; PR, prevalence ratio.